{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:14:29Z","timestamp":1761894869657},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2009,3,22]],"date-time":"2009-03-22T00:00:00Z","timestamp":1237680000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1007\/s11899-009-0015-4","type":"journal-article","created":{"date-parts":[[2009,3,21]],"date-time":"2009-03-21T05:45:21Z","timestamp":1237614321000},"page":"108-112","source":"Crossref","is-referenced-by-count":10,"title":["The role of bisphosphonates in multiple myeloma"],"prefix":"10.1007","volume":"4","author":[{"given":"Jessica","family":"Levy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. David","family":"Roodman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,3,22]]},"reference":[{"key":"15_CR1","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","volume":"80","author":"R.E. Coleman","year":"1997","unstructured":"Coleman RE: Skeletal complications of malignancy. Cancer 1997, 80: 1588\u20131594.","journal-title":"Cancer"},{"key":"15_CR2","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1359\/JBMR.041131","volume":"20","author":"L.J. Melton 3rd","year":"2005","unstructured":"Melton LJ 3rd, Kyle RA, Achenbach SJ, et al.: Fracture risk with multiple myeloma: a population-based study. J Bone Miner Res 2005, 20: 487\u2013493.","journal-title":"J Bone Miner Res"},{"key":"15_CR3","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1046\/j.1365-2141.1997.1042920.x","volume":"97","author":"T. Diamond","year":"1997","unstructured":"Diamond T, Levy S, Day P, et al.: Biochemical, histomorphometric and densitometric changes in patients with multiple myeloma: effects of glucocorticoid therapy and disease activity. Br J Haematol 1997, 97: 641\u2013648.","journal-title":"Br J Haematol"},{"key":"15_CR4","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","volume":"16","author":"J.R. Berenson","year":"1998","unstructured":"Berenson JR, Lichtenstein A, Porter L, et al.: Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 1998, 16: 593\u2013602.","journal-title":"J Clin Oncol"},{"key":"15_CR5","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","volume":"95","author":"H. Yasuda","year":"1998","unstructured":"Yasuda H, Shima N, Nakagawa N, et al.: Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and is identical to TRANCE\/RANKL. Proc Natl Acad Sci U S A 1998, 95: 3597\u20133602.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"15_CR6","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1530\/eje.0.1390152","volume":"139","author":"L.C. Hofbauer","year":"1998","unstructured":"Hofbauer LC, Heufelder AE: Osteoprotegerin and its cognate ligand: a new paradigm of osteoclastogenesis. Eur J Endocrinol 1998, 139: 152\u2013154.","journal-title":"Eur J Endocrinol"},{"key":"15_CR7","doi-asserted-by":"crossref","first-page":"11581","DOI":"10.1073\/pnas.201394498","volume":"98","author":"R.N. Pearse","year":"2001","unstructured":"Pearse RN, Sordillo EM, Yaccoby S, et al.: Multiple myeloma disrupts the TRANCE\/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A 2001, 98: 11581\u201311586.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"15_CR8","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1182\/blood-2002-09-2684","volume":"101","author":"O. Sezer","year":"2003","unstructured":"Sezer O, Heider U, Zavrski I, et al.: RANK ligand and osteoprotegerin in myeloma bone disease. Blood 2003, 101: 2094\u20132098.","journal-title":"Blood"},{"key":"15_CR9","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","volume":"93","author":"D.L. Lacey","year":"1998","unstructured":"Lacey DL, Timms E, Tan HL, et al.: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93: 165\u2013176.","journal-title":"Cell"},{"key":"15_CR10","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1182\/blood-2003-02-0380","volume":"102","author":"E. Terpos","year":"2003","unstructured":"Terpos E, Szydlo R, Apperley JF, et al.: Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 2003, 102: 1064\u20131069.","journal-title":"Blood"},{"key":"15_CR11","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1182\/blood.V97.11.3349","volume":"97","author":"J.H. Han","year":"2001","unstructured":"Han JH, Choi SJ, Kurihara N, et al.: Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood 2001, 97: 3349\u20133353.","journal-title":"Blood"},{"key":"15_CR12","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/blood.V87.4.1495.bloodjournal8741495","volume":"87","author":"M. Alsina","year":"1996","unstructured":"Alsina M, Boyce B, Devlin RD, et al.: Development of an in vivo model of human multiple myeloma bone disease. Blood 1996, 87: 1495\u20131501.","journal-title":"Blood"},{"key":"15_CR13","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1172\/JCI200113116","volume":"108","author":"S.J. Choi","year":"2001","unstructured":"Choi SJ, Oba Y, Gazitt Y, et al.: Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease. J Clin Invest 2001, 108: 1833\u20131841.","journal-title":"J Clin Invest"},{"key":"15_CR14","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1182\/blood-2003-06-1992","volume":"103","author":"J.W. Lee","year":"2004","unstructured":"Lee JW, Chung HY, Ehrlich LA, et al.: IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood 2004, 103: 2308\u20132315.","journal-title":"Blood"},{"key":"15_CR15","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1172\/JCI115584","volume":"89","author":"G.D. Roodman","year":"1992","unstructured":"Roodman GD, Kurihara N, Ohsaki Y, et al.: Interleukin 6. A potential autocrine\/paracrine factor in Paget\u2019s disease of bone. J Clin Invest 1992, 89: 46\u201352.","journal-title":"J Clin Invest"},{"key":"15_CR16","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1359\/jbmr.1999.14.2.256","volume":"14","author":"H. Hjorth-Hansen","year":"1999","unstructured":"Hjorth-Hansen H, Seifert MF, Borset M, et al.: Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice. J Bone Miner Res 1999, 14: 256\u2013263.","journal-title":"J Bone Miner Res"},{"key":"15_CR17","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","volume":"349","author":"E. Tian","year":"2003","unstructured":"Tian E, Zhan F, Walker R, et al.: The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003, 349: 2483\u20132494.","journal-title":"N Engl J Med"},{"key":"15_CR18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.gene.2004.06.044","volume":"341","author":"J.J. Westendorf","year":"2004","unstructured":"Westendorf JJ, Kahler RA, Schroeder TM: Wnt signaling in osteoblasts and bone diseases. Gene 2004, 341: 19\u201339.","journal-title":"Gene"},{"key":"15_CR19","doi-asserted-by":"crossref","first-page":"7665","DOI":"10.1158\/0008-5472.CAN-06-4666","volume":"67","author":"N. Giuliani","year":"2007","unstructured":"Giuliani N, Morandi F, Tagliaferri S, et al.: Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment. Cancer Res 2007, 67: 7665\u20137674.","journal-title":"Cancer Res"},{"key":"15_CR20","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1182\/blood-2005-03-1080","volume":"106","author":"L.A. Ehrlich","year":"2005","unstructured":"Ehrlich LA, Chung HY, Ghobrial I, et al.: IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood 2005, 106: 1407\u20131414.","journal-title":"Blood"},{"key":"15_CR21","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1182\/blood-2004-12-4986","volume":"106","author":"N. Giuliani","year":"2005","unstructured":"Giuliani N, Colla S, Morandi F, et al.: Myeloma cells block RUNX2\/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 2005, 106: 2472\u20132483.","journal-title":"Blood"},{"key":"15_CR22","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1359\/jbmr.060117","volume":"21","author":"S.K. Lee","year":"2006","unstructured":"Lee SK, Kalinowski JF, Jacquin C, et al.: Interleukin-7 influences osteoclast function in vivo but is not a critical factor in ovariectomy-induced bone loss. J Bone Miner Res 2006, 21: 695\u2013702.","journal-title":"J Bone Miner Res"},{"key":"15_CR23","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1073\/pnas.0136772100","volume":"100","author":"G. Toraldo","year":"2003","unstructured":"Toraldo G, Roggia C, Qian WP, et al.: IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. Proc Natl Acad Sci U S A 2003, 100: 125\u2013130.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"15_CR24","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2003-11-3839","volume":"104","author":"M. Abe","year":"2004","unstructured":"Abe M, Hiura K, Wilde J, et al.: Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 2004, 104: 2484\u20132491.","journal-title":"Blood"},{"key":"15_CR25","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1046\/j.1365-2141.2002.03257.x","volume":"116","author":"S. Yaccoby","year":"2002","unstructured":"Yaccoby S, Pearse RN, Johnson CL, et al.: Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 2002, 116: 278\u2013290.","journal-title":"Br J Haematol"},{"key":"15_CR26","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/cncr.11125","volume":"97","author":"P.I. Croucher","year":"2003","unstructured":"Croucher PI, Shipman CM, Van Camp B, Vanderkerken K: Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease. Cancer 2003, 97: 818\u2013824.","journal-title":"Cancer"},{"key":"15_CR27","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","volume":"334","author":"J.R. Berenson","year":"1996","unstructured":"Berenson JR, Lichtenstein A, Porter L, et al.: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 1996, 334: 488\u2013493.","journal-title":"N Engl J Med"},{"key":"15_CR28","first-page":"227","volume":"5","author":"E.V. McCloskey","year":"2003","unstructured":"McCloskey EV: Clodronate in the management of breast cancer and multiple myeloma. Ortop Traumatol Rehabil 2003, 5: 227\u2013233.","journal-title":"Ortop Traumatol Rehabil"},{"key":"15_CR29","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1586\/14737140.4.6.991","volume":"4","author":"A. Heidenreich","year":"2004","unstructured":"Heidenreich A, Ohlmann CH: Ibandronate: its pharmacology and clinical efficacy in the management of tumor-induced hypercalcemia and metastatic bone disease. Expert Rev Anticancer Ther 2004, 4: 991\u20131005.","journal-title":"Expert Rev Anticancer Ther"},{"key":"15_CR30","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1196\/annals.1402.089","volume":"1117","author":"R.G. Russell","year":"2007","unstructured":"Russell RG, Xia Z, Dunford JE, et al.: Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci 2007, 1117: 209\u2013257.","journal-title":"Ann N Y Acad Sci"},{"key":"15_CR31","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1517\/14728222.11.7.941","volume":"11","author":"S. Galluzzo","year":"2007","unstructured":"Galluzzo S, Santini D, Vincenzi B, et al.: Immunomodulating role of bisphosphonates on human gamma delta T cells: an intriguing and promising aspect of their antitumour activity. Expert Opin Ther Targets 2007, 11: 941\u2013954.","journal-title":"Expert Opin Ther Targets"},{"key":"15_CR32","first-page":"5294","volume":"58","author":"C.M. Shipman","year":"1998","unstructured":"Shipman CM, Croucher PI, Russell RG, et al.: The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 1998, 58: 5294\u20135297.","journal-title":"Cancer Res"},{"key":"15_CR33","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1046\/j.1365-2141.2002.03824.x","volume":"119","author":"S. Gordon","year":"2002","unstructured":"Gordon S, Helfrich MH, Sati HI, et al.: Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma. Br J Haematol 2002, 119: 475\u2013483.","journal-title":"Br J Haematol"},{"key":"15_CR34","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/MED.0b013e3283184017","volume":"15","author":"S.M. Arum","year":"2008","unstructured":"Arum SM: New developments surrounding the safety of bisphosphonates. Curr Opin Endocrinol Diabetes Obes 2008, 15: 508\u2013513.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"15_CR35","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1445-5994.1996.tb01932.x","volume":"26","author":"G.O. Stewart","year":"1996","unstructured":"Stewart GO, Stuckey BG, Ward LC, et al.: Iritis following intravenous pamidronate. Aust N Z J Med 1996, 26: 414\u2013415.","journal-title":"Aust N Z J Med"},{"key":"15_CR36","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/sj.bjc.6604382","volume":"98","author":"R.E. Coleman","year":"2008","unstructured":"Coleman RE: Risks and benefits of bisphosphonates. Br J Cancer 2008, 98: 1736\u20131740.","journal-title":"Br J Cancer"},{"key":"15_CR37","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.2005.04.2465","volume":"24","author":"A. Badros","year":"2006","unstructured":"Badros A, Weikel D, Salama A, et al.: Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006, 24: 945\u2013952.","journal-title":"J Clin Oncol"},{"key":"15_CR38","doi-asserted-by":"crossref","unstructured":"Badros A, Evangelos T, Goloubeva O, et al.: Long-term follow-up of multiple myeloma (MM) patients (pts) with osteonecrosis of the jaw (ONJ) [poster]. Blood (ASH Annual Meeting Abstracts) 2007, 110: Abstract 3519.","DOI":"10.1182\/blood.V110.11.3519.3519"},{"key":"15_CR39","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1200\/JCO.2007.12.1269","volume":"25","author":"R.A. Kyle","year":"2007","unstructured":"Kyle RA, Yee GC, Somerfield MR, et al.: American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007, 25: 2464\u20132472.","journal-title":"J Clin Oncol"},{"key":"15_CR40","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.4065\/81.8.1047","volume":"81","author":"M.Q. Lacy","year":"2006","unstructured":"Lacy MQ, Dispenzieri A, Gertz MA, et al.: Mayo Clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 2006, 81: 1047\u20131053.","journal-title":"Mayo Clin Proc"},{"key":"15_CR41","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","volume":"22","author":"S. Khosla","year":"2007","unstructured":"Khosla S, Burr D, Cauley J, et al.: Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007, 22: 1479\u20131491.","journal-title":"J Bone Miner Res"},{"key":"15_CR42","doi-asserted-by":"crossref","unstructured":"Vij R, Horvath N, Spencer A, et al.: An open-label, phase 2 trial of denosumab in the treatment of relapsed (R) or plateau-phase (PP) multiple myeloma (MM) [poster]. Blood (ASH Annual Meeting Abstracts) 2007, 110: Abstract 3604.","DOI":"10.1182\/blood.V110.11.3604.3604"},{"key":"15_CR43","first-page":"491","volume":"118","author":"S. Mukherjee","year":"2008","unstructured":"Mukherjee S, Raje N, Schoonmaker JA, et al.: Pharmacologic targeting of a stem\/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest 2008, 118: 491\u2013504.","journal-title":"J Clin Invest"},{"key":"15_CR44","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1365-2141.2007.06829.x","volume":"139","author":"B.O. Oyajobi","year":"2007","unstructured":"Oyajobi BO, Garrett IR, Gupta A, et al.: Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease. Br J Haematol 2007, 139: 434\u2013438.","journal-title":"Br J Haematol"},{"key":"15_CR45","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/blood-2006-11-059188","volume":"110","author":"N. Giuliani","year":"2007","unstructured":"Giuliani N, Morandi F, Tagliaferri S, et al.: The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 2007, 110: 334\u2013338.","journal-title":"Blood"},{"key":"15_CR46","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/j.1365-2141.2006.06356.x","volume":"135","author":"E. Terpos","year":"2006","unstructured":"Terpos E, Heath DJ, Rahemtulla A, et al.: Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol 2006, 135: 688\u2013692.","journal-title":"Br J Haematol"},{"key":"15_CR47","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1182\/blood-2005-08-3450","volume":"107","author":"G. Anderson","year":"2006","unstructured":"Anderson G, Gries M, Kurihara N, et al.: Thalidomide derivative CC-4047 inhibits osteoclast formation by downregulation of PU.1. Blood 2006, 107: 3098\u20133105.","journal-title":"Blood"},{"key":"15_CR48","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/leu.2008.174","volume":"22","author":"I. Breitkreutz","year":"2008","unstructured":"Breitkreutz I, Raab MS, Vallet S, et al.: Lenalidomide inhibits osteoclastogenesis, survival factors and boneremodeling markers in multiple myeloma. Leukemia 2008, 22: 1925\u20131932.","journal-title":"Leukemia"},{"key":"15_CR49","doi-asserted-by":"crossref","unstructured":"Heath DJ, Chantry AD, Buckle CH, et al.: Inhibiting dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J Bone Miner Res 2008 Nov 18 (Epub ahead of print).","DOI":"10.1359\/jbmr.081104"},{"key":"15_CR50","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood-2006-09-047712","volume":"109","author":"S. Yaccoby","year":"2007","unstructured":"Yaccoby S, Ling W, Zhan F, et al.: Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 2007, 109: 2106\u20132111.","journal-title":"Blood"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-009-0015-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-009-0015-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-009-0015-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:03:58Z","timestamp":1710201838000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-009-0015-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,22]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["15"],"URL":"https:\/\/doi.org\/10.1007\/s11899-009-0015-4","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3,22]]}}}